Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)

BOSTON ( TheStreet) -- The five best-performing biotech and drug stocks as we near the midway point in 2013:

1. Clovis Oncology ( CLVS) CLVS Chart CLVS data by YCharts

Clovis had "only" doubled in value through May 31 when the stock really took off following the presentation of data from a phase I study of its lung cancer drug CO-1686 at the American Society of Clinical Oncology (ASCO) annual meeting. When I say "data," I'm barely talking about the plural, given the small number of patients treated in the study. But tumor shrinkage reported with CO-1686 treatment was impressive, particularly in lung cancer patients with a specific mutation that made their tumors unresponsive to currently approved drugs.

Remember when Clovis' previously lead pancreatic cancer drug CO-101 failed a phase III study last year? Yeah, old news and forgotten. Today, analysts and investors are fawning all over CO-1686, predicting Clovis will drastically accelerate development and get the lung cancer drug approved in three years. The company still has to figure out a most-effective dose, work on a pill formulation and design/conduct a pivotal study, but no worries...

On Monday, Clovis announced plans to sell stock to raise as much as $170 million. On that news, Clovis shares went up! There's your biotech bull market in action.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

Clovis Sell-Off May Be Overdone

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why